# Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

> **NCT05900206** · PHASE2 · RECRUITING · sponsor: **Karolinska University Hospital** · enrollment: 370 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Ribociclib
- **DRUG:** Letrozole
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05900206
- **Lead sponsor:** Karolinska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-26
- **Primary completion:** 2027-04-30
- **Final completion:** 2032-04-30
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05900206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05900206, "Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05900206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*